AdvertiseDonate
☰ SectionsThe latest from the cities that shape the country.
Wire Authority · 3970 Post Road, Warwick, RI 02886

New Pancreatic Cancer Pill Offers Hope for Long-Term Remission

A new oral drug has shown the ability to shrink or eliminate pancreatic tumors in clinical trials, offering a significant improvement in survival rates for patients with advanced disease.

By News Media House Staff ·

Illustration for: New Pancreatic Cancer Pill Offers Hope for Long-Term Remission
Illustration generated for this article, not a news photograph.

A new oral medication designed to treat pancreatic cancer is generating significant optimism in the medical community, with experts describing it as a major breakthrough in the field. The drug, known as daraxonrasib, has demonstrated the ability to shrink tumors and, in some cases, make them completely undetectable on scans. This development marks a significant shift in the approach to one of the most lethal forms of cancer.

Clinical trial data revealed that among the participants, the cancer became undetectable in approximately one in twelve patients. The study involved sixty-one individuals who had recently been diagnosed with advanced pancreatic cancer that had already spread to other parts of their bodies. For nearly all of these patients, the tumors stopped growing after they began taking the medication.

While medical professionals caution that the pill is not yet considered a definitive cure, they emphasize that the results are highly encouraging. The treatment appears to extend the time patients can live, even if it does not result in a full remission for everyone. Currently, pancreatic cancer has the lowest survival rate among common cancers in the UK, with half of all diagnosed patients dying within three months of diagnosis.

The statistical outlook for patients with metastatic pancreatic cancer has historically been grim, with only about three percent surviving for five years. The new trial data offers a stark contrast to these historical figures. Patients in the study were monitored for an average of eighteen months. During this period, some participants did not see their cancer return, and longer studies are now planned to determine if the drug can induce lasting remission.

Specific outcomes from the trial indicate that tumors stopped growing in ninety percent of the patients. Just over sixty percent of participants experienced a reduction in tumor size or a complete disappearance of the tumors. For roughly eight percent of the group, the tumors became undetectable on CT scans. Survival rates also showed a marked improvement compared to standard treatments.

One year after initiating treatment, seventy-six point six percent of the patients were still alive. This figure stands in contrast to the usual survival rate for patients receiving chemotherapy alone, which is typically between forty and forty-five percent after one year. The data suggests that the new treatment may significantly alter the trajectory of the disease for many individuals.

Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, presented the findings at a recent symposium in Barcelona. He described the results as the closest to a cure he had seen, noting that he had never witnessed so many tumors disappear in patients whose cancer had metastasized. He highlighted the deeper responses and the near doubling in the duration of disease control observed in the trial.

Daraxonrasib functions as a KRAS inhibitor. It works by targeting and shutting off specific mutations found in the majority of pancreatic cancer cases. These mutations are known to drive tumor growth. Because similar mutations can occur in other types of cancer, there is hope that this treatment approach could eventually be applied to dozens of other malignancies.

Michelle Mitchell, the chief executive of Cancer Research UK, stated that while further research is necessary, this represents the biggest leap forward for pancreatic cancer patients in decades. She noted that the results offer real hope to those facing a difficult-to-treat disease. Mitchell added that the breakthrough could pave the way for treating other cancers with Kras gene mutations, though more trials are needed before the treatment can be assessed for use on the NHS.

Originally published by News Media House

More World · Report a business · Got a Story?

Get Wire Authority in your inboxThe latest from the cities that shape the country. Free, a few times a week, unsubscribe any time.

Related stories

Latest stories

  1. Top Online Sportsbooks Offer Nearly $4,000 in NBA Betting Promos for Nov. 20
  2. Three Arab men shot dead in Israel within a single day
  3. Tashima Remains in FIFA Presidential Race Against Infantino
  4. German Youth Rally to Resist Military Expansion and Rising Defense Costs
  5. A24 box office surge strengthens HBO Max streaming position
Get Wire Authority in your inboxThe latest from the cities that shape the country. Free, a few times a week, unsubscribe any time.